Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Anixa Biosciences, Inc. (ANIX)
Last anixa biosciences, inc. earnings: 3/9 05:10 pm
Check Earnings Report
Company Research
Source: PR Newswire
Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August 2025[1] signaled the recent wave of regulatory momentum behind next-generation therapies. Meanwhile, advanced treatment platforms are achieving complete tumor elimination in clinical trials across multiple cancer types[2]. These developments position Oncolytics Biotech Inc. (NASDAQ: ONCY), Anixa Biosciences, Inc. (NASDAQ: ANIX), IceCure Medical Ltd. (NASDAQ: ICCM), ImmunityBio, Inc. (NASDAQ: IBRX), and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).Industry analysts at Exactitude Consultancy project the cancer immunotherapy market will reach $258.22 billion by 2031[3], driven by breakthrough treatment platforms and precision technologies that are transforming how tumors are detected and destroyed. The convergence of FDA fast-track approvals, revolutionary immune-based treatments, and innovative the
Show less
Read more
Impact Snapshot
Event Time:
ANIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIX alerts
High impacting Anixa Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ANIX
News
- Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization [Yahoo! Finance]Yahoo! Finance
- Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future CommercializationPR Newswire
- Anixa Biosciences (NASDAQ:ANIX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Anixa Biosciences: Hard To Justify The Market's Optimism With An Upcoming Phase 1 Readout [Seeking Alpha]Seeking Alpha
- Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040sPR Newswire
ANIX
Earnings
- 9/10/25 - Beat
ANIX
Analyst Actions
- 9/11/25 - HC Wainwright
ANIX
Sec Filings
- 10/31/25 - Form 4
- 10/1/25 - Form EFFECT
- 9/10/25 - Form S-3
- ANIX's page on the SEC website